The case of successful therapy with rituximab secondary hemolytic-uremic syndrome in a patient after the second allogeneic hematopoietic stem cell transplantation
https://doi.org/10.17650/2311-1267-2016-3-3-61-65
Abstract
Transplant-associated thrombotic microangiopathy (TA-TMA) is rare but very unfavour multifactorial complication of allogenic hematopoietic stem cell transplantation (HSCT). Diagnostics of TA-TMA complicated by non-specificity of clinical signs and histological picture, as well as its frequent appearance in the background of other complications of HSCT. Currently there are no clear recommendations for TA-TMA treatment. This clinical case demonstrates manifestation of TA-TMA as hemolytic-uremic syndrome at the patient in 4th remission of acute lymphoblastic leukemia on the early stages after the second allogenic HSCT. Possibility of successful rituximab therapy with condition stabilization and TA-TMA resolving demonstrated.
About the Authors
E. A. Pristanskova
Russian Children's Clinical Hospital, Ministry of Health of Russia
Russian Federation
117 Leninskiy Prosp., Moscow, 117997
Russian Federation
117 Leninskiy Prosp., Moscow, 117997
K. I. Kirgizov
Russian Children's Clinical Hospital, Ministry of Health of Russia;
Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia
Russian Federation
Russian Federation
117 Leninskiy Prosp., Moscow, 117997;
1 Samory Mashela St., Moscow, 117997
N. V. Sidorova
Russian Children's Clinical Hospital, Ministry of Health of Russia
Russian Federation
117 Leninskiy Prosp., Moscow, 117997
Russian Federation
117 Leninskiy Prosp., Moscow, 117997
V. V. Konstantinova
Russian Children's Clinical Hospital, Ministry of Health of Russia
Russian Federation
117 Leninskiy Prosp., Moscow, 117997
Russian Federation
117 Leninskiy Prosp., Moscow, 117997
A. E. Burya
Russian Children's Clinical Hospital, Ministry of Health of Russia
Russian Federation
117 Leninskiy Prosp., Moscow, 117997
Russian Federation
117 Leninskiy Prosp., Moscow, 117997
E. V. Skorobogatova
Russian Children's Clinical Hospital, Ministry of Health of Russia
Russian Federation
117 Leninskiy Prosp., Moscow, 117997
Russian Federation
117 Leninskiy Prosp., Moscow, 117997
References
1. Lerner D., Dandoy C., Hirsch R. еt al. Pericardial effusion in pediatric SCT recipients with thrombotic microangiopathy. Bone Marrow Transplant 2014;49(6):862–3.
2. Inamoto Y., Ito M., Suzuki R. еt al. Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy. Bone Marrow Transplant 2009;44(1):43–9.
3. Fujino M., Kim Y., Ito M. Intestinal thrombotic microangiopathy induced by FK506 in rats. Bone Marrow Transplant 2007;39(6):367–72.
4. Batts E.D., Lazarus H.M. Diagnosis and treatment of transplantation-associated throm-botic microangiopathy: real progress or are we still waiting? Bone Marrow Transplant 2007;40(8):709–19.
5. Labrador J., Lόpez-Corral L., Lόpez-Godino O. еt al. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus. Bone Marrow Transplant 2014;49(5):684–90.
6. Laskin B.L., Goebel J., Davies S.M., Jodele S. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation–associated thrombotic microangiopathy. Blood 2011;118(6):1452–62.
7. Vesely S.K., George J.N., Lammle B. еt al. ADAMTS13 activity in thrombotic throm-bocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003;102(1):60 –8.
8. Kentouche K., Zintl F., Angerhaus D. еt al. von Willebrand factor-cleaving protease (ADAMTS13) in the course of stem cell transplantation. Semin Thromb Hemost 2006;32(2):98–104.
9. Cho B.S., Min C.K., Eom K.S. еt al. Clinical impact of thrombotic microangiopathy on the outcome of patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008;41(9):813–20.
10. Goyama S., Takeuchi K., Kanda Y. еt al. Рost-transplant endothelial disorder after hematopoietic SCT: a blinded autopsy study. Bone Marrow Transplant 2012;47(9):1243–5.
11. Besbas N., Karpman D., Landau D. еt al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 2006;70(3):423–31.
12. Ostronoff M., Ostronoff F., Calixto R. еt al. Life-threatening hemolytic-uremic syndrome treated with rituximab in an allogeneic bone marrow transplant recipient. Bone Marrow Transplant 2007;39(10):649–51.
13. Mateos J., Pérez-Simón J.A., Caballero D. еt al. Vincristine is an effective therapeutic approach for transplantation-associated thrombotic microangiopathy. Bone Marrow Transplant 2006;37(3):337–8.
14. Ohno E., Ohtsuka E., Iwashita T. еt al. Hemolytic uremic syndrome following autologous peripheral blood stem cell transplantation in a patient with malignant lymphoma. Bone Marrow Transplant 1997;19(10):1045–7.
15. Okano M., Sakata N., Ueda S., Takemura T. Recovery from life-threatening trans-plantation-associated thrombotic microangiopathy using eculizumab in a patient with very severe aplastic anemia. Bone Marrow Transplant 2014;49(8):1116–8.
Review
For citations:
Pristanskova E.A., Kirgizov K.I., Sidorova N.V., Konstantinova V.V., Burya A.E., Skorobogatova E.V. The case of successful therapy with rituximab secondary hemolytic-uremic syndrome in a patient after the second allogeneic hematopoietic stem cell transplantation. Russian Journal of Pediatric Hematology and Oncology. 2016;3(3):61-65. (In Russ.) https://doi.org/10.17650/2311-1267-2016-3-3-61-65
Views:
694
Email this article 